Article
Pharmacology & Pharmacy
Beatriz Orts, Ana Gutierrez, Lucia Madero, Laura Sempere, Ruben Frances, Pedro Zapater
Summary: There are differences in the immunological profile and clinical evolution of patients with Crohn's disease according to the anti-TNF dose and serum trough levels.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Gilles Boschetti, Maria Nachury, David Laharie, Xavier Roblin, Cyrielle Gilletta, Alexandre Aubourg, Arnaud Bourreille, Camille Zallot, Xavier Hebuterne, Anthony Buisson, Jean-Charles Grimaud, Yoram Bouhnik, Matthieu Allez, Romain Altwegg, Stephanie Viennot, Lucine Vuitton, Franck Carbonnel, Stephane Paul, Kristell Desseaux, Jerome Lambert, Laurent Peyrin-Biroulet
Summary: This study aimed to investigate the efficacy and safety of infliximab (IFX) reintroduction in Crohn's disease (CD) after discontinuation due to loss of response or intolerance. The results showed that IFX retreatment was effective and safe in approximately one-third of patients with CD, regardless of the reason for prior discontinuation. Early detection of anti-drug antibodies could predict subsequent failure of IFX reintroduction and infusion reactions.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, Parambir S. Dulai, Neil K. Sengupta, John K. Marshall, Jean-Frederic Colombel, Walter Reinisch
Summary: This post hoc analysis suggests that infliximab and ustekinumab have similar efficacy and speed of onset in biologic-naive patients with CD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Immunology
Chenglin Ye, Sizhe Zhu, Jingping Yuan
Summary: This study analyzed the gene expression profiles of patients with Crohn's disease (CD) and identified two gene subtypes: immune and metabolic. The immune subtype was associated with leukocyte migration and cytokine interactions, while the metabolic subtype was associated with metabolic pathways. The combination of interleukin 1 beta, interleukin 6, and Toll-like receptor 4 effectively distinguished between these two gene subtypes.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Hua-Hua Yang, Yi Huang, Xu-Chun Zhou, Ruo-Nan Wang
Summary: The study found that there was no significant difference between ADA and IFX in inducing response, maintaining response, and loss of response in the treatment of Crohn's disease, but ADA had fewer overall adverse events than IFX.
WORLD JOURNAL OF CLINICAL CASES
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chen Yueying, Feng Jing, Feng Qi, Shen Jun
Summary: A magnetic resonance enterography-based model was constructed in this study to predict the risk of loss of response to infliximab (IFX) in bio-naive patients with Crohn's disease (CD), providing an effective tool for the early estimation of treatment response before biological intervention.
EUROPEAN RADIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Rahul S. Dalal, Emma L. McClure, Jenna Marcus, Jessica R. Allegretti
Summary: This study compared the long-term drug survival of vedolizumab, adalimumab, and infliximab in patients with ulcerative colitis (UC). The results showed that vedolizumab had better survival rates than adalimumab for both clinical response and adverse effects, and vedolizumab also had better survival rates than infliximab for adverse effects.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Laura Maas, Ruiyi Gao, Vivy Cusumano, Ellen Spartz, Reezwana Chowdhury, Mahesh Krishna, Mark Lazarev, Joanna Melia, Florin Selaru, Sowmya Sharma, Berkeley Limketkai, Alyssa Parian
Summary: This study compared the efficacy of infliximab (IFX) and adalimumab (ADA) in healing CD-PAF. The results showed that the IFX group had better clinical response at 6 months and higher biologic persistence. In addition, the study supported the use of concomitant immunomodulator therapy for CD-PAF healing and remission.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Yoon-Zi Kim, Ben Kang, Eun-Sil Kim, Yiyoung Kwon, Yon-Ho Choe, Mi-Jin Kim
Summary: This study compared the efficacy and immunogenicity of methotrexate (MTX) and azathioprine (AZA) as concurrent therapies for pediatric Crohn's disease (CD). The results showed that there were no significant differences in remission rates between the two medications, and they both effectively maintained adequate Infliximab (IFX) levels and reduced anti-drug antibody (ADA) production.
Review
Pharmacology & Pharmacy
Anji Xiong, Deng Liu, Huini Chen, Guancui Yang, Chen Xiong, Yu Shuai, Linqian He, Zepeng Guo, Liangwen Zhang, Yuan Yang, Beibei Cui, Shiquan Shuai
Summary: The study demonstrates that infliximab shows good efficacy in controlling intraocular inflammation, improving visual acuity, and sparing corticosteroid use in refractory noninfectious uveitis. However, adverse events such as hypersensitivity reactions, serious infections, autoimmune diseases, and neoplasia may occur in some patients.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Biao Li, Haoran Li, Li Zhang, Yanlin Zheng
Summary: This meta-analysis of six RCTs confirmed that adalimumab (ADA) significantly reduced the risk of treatment failure or visual loss in noninfectious uveitis (NIU) patients, while moderately decreasing anterior chamber cell grades and vitreous haze grades, although leading to slightly more adverse events.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
C. Erdogan, M. B. Durak, A. Alkan, V. Kilic, F. Kivrakoglu, K. Kosar, I. Yuksel
Summary: This study evaluated the long-term clinical effectiveness and safety of infliximab (IFX) and adalimumab (ADA) in Crohn's disease patients who had not previously received a biologic treatment. The results showed no significant differences in the long-term effectiveness and safety of IFX and ADA in biologic-naive patients with CD.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Emily C. L. Wong, Parambir S. Dulai, John K. Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula
Summary: In this post hoc analysis, treatment with infliximab and ustekinumab achieved 1-year clinical remission with similar efficacy among biologic-naive Crohn's disease patients who responded to induction therapy. However, infliximab may confer greater benefit for endoscopic outcomes.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Haggai Bar-Yoseph, Alexandra Blatt, Shiran Gerassy, Sigal Pressman, Amjad Mousa, Edmond Sabo, Matti Waterman, Bella Ungar, Shomron Ben-Horin, Yehuda Chowers
Summary: Therapeutic drug monitoring is essential when guiding anti-TNF therapy for inflammatory bowel disease. This study found differences in tissue dynamics between infliximab and adalimumab, with SDL correlating with tissue free drug levels. Understanding these interactions could lead to improved therapeutic strategies in the future.
JOURNAL OF CROHNS & COLITIS
(2022)
Review
Gastroenterology & Hepatology
Eun Sil Kim, Ben Kang
Summary: The selection of biologic agents for pediatric Crohn's disease should be done carefully, as currently only infliximab and adalimumab are approved for use in children. Lack of comparison trials in pediatric patients necessitates the extrapolation of adult data. From a pharmacokinetic perspective, infliximab may be more advantageous in high inflammatory burden, while adalimumab may be better in sustaining remission during maintenance phase. Factors such as clinical indications, disease behavior, efficacy, safety, immunogenicity, patient preference, and compliance should be considered when choosing anti-TNF therapy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)